TTY Biopharm Co

TTY Biopharm Co EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of TTY Biopharm Co (4105.TWO) as of Nov 3, 2026 is 12.44. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 17.90 — a change of -30.51% (lower).

EV/FCF

12.44

YoY

-30.51%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of TTY Biopharm Co is 2025 12.44 . EV/FCF (Enterprise Value to Free Cash Flow) of TTY Biopharm Co was 2024 17.90 . It decreases by -30.51% lower compared to the previous year.

The TTY Biopharm Co EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
21.55 TWD
Jan 1, 2019
19.28 TWD
Jan 1, 2020
56.95 TWD
Jan 1, 2021
16.55 TWD
Jan 1, 2022
17.42 TWD
Jan 1, 2023
19.36 TWD
Jan 1, 2024
17.90 TWD
Jan 1, 2025
12.44 TWD
The TTY Biopharm Co EV/FCF history
YEAREV/FCFYoY
12.44-30.51%
17.90-7.53%
19.36+11.16%
17.42+5.21%
16.55-70.93%
56.95+195.44%
19.28-10.54%
21.55-12.83%
24.72+46.43%
16.88-61.17%
43.47-123.23%
-187.18—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TTY Biopharm Co Stock analysis

What does TTY Biopharm Co do? TTY Biopharm Co Ltd generates revenue through pharmaceutical and chemical drug production, primarily targeting domestic and overseas markets. The company's six business segments include Cancer Drug, Healthcare, Anti-Infective Drug, Domestic Cardiovascular and Gastrointestinal Drug, Mainland Medical Drug, and Other segments. Key products are oncology medicines such as anti-cancer and auxiliary drugs, anti-infective medicines like back-line antimicrobial agents and influenza vaccines, and healthcare medicines covering gastrointestinal, bone, metabolic health care, and infection treatment. Domestic and overseas customers purchase these products through the company's distribution channels. The Cancer Drug segment focuses on oncology medicines, including anti-cancer and auxiliary drugs, while the Anti-Infective Drug segment offers back-line antimicrobial agents and influenza vaccines. Healthcare segment products target gastrointestinal, bone, and metabolic health care, alongside infection treatment drugs. Mainland Medical Drug segment serves the mainland market with medical drugs, and Other segment handles additional product lines. All products are distributed domestically and internationally. Domestic and overseas markets drive sales of TTY Biopharm's pharmaceutical portfolio. Customers include healthcare providers and distributors purchasing oncology, anti-infective, and healthcare medicines. The Mainland Medical Drug segment specifically caters to the mainland market, while other segments serve broader regional demands. Product distribution spans both local and global channels. TTY Biopharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TTY Biopharm Co stock

EV/FCF (Enterprise Value to Free Cash Flow) of TTY Biopharm Co is 12.44 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of TTY Biopharm Co changed from 17.90 to 12.44, representing a -30.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) TTY Biopharm Co since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s TTY Biopharm Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — TTY Biopharm Co

All Key Metrics — TTY Biopharm Co